BridgeMD
New treatment option for Retinal Detachment
Official title Nicotinamide Riboside Oral Supplementation in Macula Off Retinal Detachment
ClinicalTrials.gov ID: NCT06587945
What this study is testing
- What it's testing
- Retinal detachment occurs when fluid separates the retina (a thin, light sensing tissue) from its usual attachment at the back of the eye. If detached, these retinal cells lose their normal blood supply and begin to die, which is the primary cause of vision loss in retinal detachment.
- Phase 4: studies an already-approved treatment
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years old
- Able to give informed consent and comply with all study visits and procedures.
- Present within 10 days of macula-off retinal detachment (based on patient-reported history of loss of central vision)
- Present to the hospital with a visual acuity of hand motion or better in the study eye
- Have had previous cataract surgery in the study eye
You likely can't join if
- Any known significant ocular disease in the study eye (e.g., cornea opacity) which, in the opinion of the investigator, would preclude a visual...
- Any other ocular pathology in the study eye requiring treatment with topical ophthalmic drops or intravitreal injection.
- History of previous ocular surgery in the study eye other than uncomplicated cataract surgery with posterior chamber intraocular lens and intact...
- Participation in other clinical trials or use of any other investigational drugs or devices within 3 months prior to study participation.
- Females who are pregnant or lactating and women of childbearing potential.
- Known retinopathy, known hepatic disease (or history of significant chronic liver disease), or known renal disease. Patients Participants with...
See the full eligibility criteria
- Age ≥ 18 years old
- Able to give informed consent and comply with all study visits and procedures.
- Present within 10 days of macula-off retinal detachment (based on patient-reported history of loss of central vision)
- Present to the hospital with a visual acuity of hand motion or better in the study eye
- Have had previous cataract surgery in the study eye
- Have clinical indication for standard retinal reattachment surgery by means of a pars plana vitrectomy and gas tamponade
- In the opinion of the investigator, be able to safely undergo all study procedures. Key
- Any known significant ocular disease in the study eye (e.g., cornea opacity) which, in the opinion of the investigator, would preclude a visual acuity of at least 6/7.5 (20/25) following successful vitrectomy or limit...
- Any other ocular pathology in the study eye requiring treatment with topical ophthalmic drops or intravitreal injection.
- History of previous ocular surgery in the study eye other than uncomplicated cataract surgery with posterior chamber intraocular lens and intact posterior capsule or a refractive surgery (surgery must have occurred at...
- Participation in other clinical trials or use of any other investigational drugs or devices within 3 months prior to study participation.
- Females who are pregnant or lactating and women of childbearing potential.
- Known retinopathy, known hepatic disease (or history of significant chronic liver disease), or known renal disease. Patients Participants with diabetes and no known retinopathy may be enrolled.
- History of uncontrolled hypertension.
- History of stroke, transient ischemic attack, or major cardiac surgery within 3 months prior to study, or current treatment for systemic infection.
- Any ocular or systemic condition that in the opinion of the investigator could compromise the safety of the patientparticipant, or may interfere with the safety and side effects assessments or study procedures of the...
The study team makes the final eligibility decision.
Where it's taking place
- East Melbourne, Victoria, Australia
- Geelong, Victoria, Australia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include East Melbourne, Victoria, Australia; Geelong, Victoria, Australia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.